Beyond mainstream: Making the case for fecal bacteriotherapy

Nursing

Volumn 41, Issue 12, 2011, Pages 50-53

  Myers, Frank ^a  

^a SCRIPPS MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOLOGICAL THERAPY; CLINICAL NURSING RESEARCH; CLOSTRIDIUM DIFFICILE; DIARRHEA; FECES; HUMAN; METHODOLOGY; MICROBIOLOGY; NURSING; NURSING METHODOLOGY RESEARCH; PSEUDOMEMBRANOUS COLITIS; RECURRENT DISEASE; TREATMENT OUTCOME;

BIOLOGICAL THERAPY; CLINICAL NURSING RESEARCH; CLOSTRIDIUM DIFFICILE; DIARRHEA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; HUMANS; NURSING METHODOLOGY RESEARCH; RECURRENCE; TREATMENT OUTCOME;

EID: 83055179017     PISSN: 03604039     EISSN: 15388689     Source Type: Journal    
DOI: 10.1097/01.NURSE.0000407677.74012.2f     Document Type: Article

References (25)

1. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431-455.
2. Bakken #168a; Gerding #168b. Presented at: the IDSA 48th Annual Meeting; Oct. 21-24 2010; Vancouver, B.C.
3. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36(5):580-585. (Pubitemid 36259562)
4. Nieuwdorp M, van Nood E, Speelman P, et al. Behandeling van recidiverende Clostridium difficile-geassocieerde diarree met een suspensie van donor-feces [Treatment of recurrent Clostridium difficile-associated diarrhea with a suspension of donor feces]. Ned Tijdschr Geneeskd. 2008;152(35):1927-1932.
5. Henrich TJ, Krakower D, Bitton A, Yokoe DS. Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis [serial on the Internet]. 2009;15(3):415-422. http://www.cdc. gov/EID/content/15/3/415.htm.
6. Elixhauser A, Jhung M. "Clostridium difficile-associated disease in U.S. hospitals, 1993-2005" Agency for Healthcare Research and Quality 2008; HCUP Statistical Brief #50.
7. Centers for Disease Control and Prevention (CDC). Severe Clostridium difficile-a ssociated disease in populations previously at low risk\- four states, 2005. MMWR Morb Mortal Wkly Rep. 2005;54(47):1201-1205.
8. Pituch H. Clostridium difficile is no longer just a nosocomial infection or an infection of adults. Int J Antimicrob Agents. 2009;33(suppl 1):S42-S45.
9. McDonald LC, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353(23):2433-2441. (Pubitemid 41770164)
10. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald LC, Limbago BM. Clostridium difficile in retail meat products, USA, 2007. Emerg Infect Dis [serial on the Internet]. 2009;15(5):819-821. http:// www.cdc.gov/EID/content/ 1505/819.htm.
11. Terhes G, Urbán E, Sóki J, Nacsa E, Nagy E. Comparison of a rapid molecular method, the BD GeneOhm Cdiff assay, to the most frequently used laboratory tests for detection of toxin-producing Clostridium difficile in diarrheal feces. J Clin Microbiol. 2009;47(11):3478-3481.
12. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol. 2005;54(Pt 2):101-111. (Pubitemid 40867993)
13. Siegel JD, Rhinehart E, Jackson M, Chiarello L, Healthcare Infection Control Practices Advisory Committee. 2007 guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings. http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf
14. Guide to the Elimination of Clostridium difficile in Healthcare Settings. Washington, DC: APIC; 2008.
15. Yokoe DS, Mermel LA, Anderson DJ, et al. A compendium of strategies to prevent healthcare-associated infections in acute care hospitals. Infect Control Hosp Epidemiol. 2008;29(suppl 1):S12-S21.
16. Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet. 2001;357(9251):189-193. (Pubitemid 32108091)
17. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010;362(3):197-205.
18. Miller M. The fascination with probiotics for Clostridium difficile infection: lack of evidence for prophylactic or therapeutic efficacy. Anaerobe. 2009;15(6):281-284.
19. Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636-1641.
20. Land MH, Rouster-Stevens K, Woods CR, Cannon ML, Cnota J, Shetty AK. Lactobacillus sepsis associated with probiotic therapy. Pediatrics. 2005;115(1):178-181. (Pubitemid 43046298)
21. Riquelme A, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia alter Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003;36(1):41-43. (Pubitemid 36005347)
22. Gustafsson A, Berstad A, Lund-Tønnesen S, Midtvedt T, Norin E. The effect of faecal enema on five microflora-associated characteristics in patients with antibiotic-associated diarrhoea. Scand J Gastroenterol. 1999;34(6):580-586. (Pubitemid 29339211)
23. Schwan A, Sjölin S, Trottestam U, Aronsson B. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984;16(2):211-215. (Pubitemid 14104160)
24. Vrieze A, et al "Metabolic effects of transplanting gut microbiota from lean donors to subjects with metabolic syndrome" EASD 2010; Abstract 90.
25. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958;44(5):854-859.